Clinical Pathways

Administrator Seema Verma said the proposal would create opportunities "for drug manufacturers to have skin in the game through payment arrangements that challenge them to put their money where their mouth is."

Researchers warned that financial incentives that focus on a percentage of pathway compliance could “paradoxically harm the quality of care."

Three abstracts presented at this year’s annual meeting of the American Society of Clinical Oncology focused on cardiotoxic effects of cancer treatment and how cardiac disease remains a barrier to effective cancer therapy among patients with cancer and survivors.

CMS Administrator Seema Verma announced the update today in a blog post in Health Affairs.

Debra A. Patt, MD, MPH, MBA, a breast cancer specialist at Texas Oncology is the lead author on the study being presented at ASCO.

To help patients and their caregivers cope, the National Comprehensive Cancer Network (NCCN) this week completed a 3-book series that explains care and management options for those with head and neck cancer.

More than one-quarter of elderly women with HER2-negative metastatic breast cancer did not receive care in accordance with National Comprehensive Cancer Network (NCCN) treatment guidelines, and that was linked to higher mortality as well as higher Medicare costs.

Findings from the American Society for Radiation Oncology (ASTRO) highlight the growing financial strain at freestanding clinics, including those that say they will lose half their annual revenue.

Cancer Care Specialists of Illinois was able to reduce its median total drug spend by a notable 13.5%—$250,000 per medical oncologist—versus other practices enrolled in the Oncology Care Model, between the first quarters of 2017 and 2019, through the use of evidence-based clinical pathways.

With our current issue of Evidence-Based Oncology™ focusing on clinical pathways in cancer care, we look back at one of our most-read papers of 2016.

With patients living longer thanks to new therapies, we need more accurate, sensitive, and standardized tools to guide their therapy.

As the cost of oncology drugs only continues to rise, incorporating clinical pathways into cancer care helps streamline the integration of evidence-based best practices while improving quality and reducing costs for patients and payers.

As cancer care becomes more complex and more expensive, decision-support algorithms offer a mechanism to define best practice, reduce unwarranted variation, and control costs across growing networks.

The authors examined the latest trends in development, implementation, and evaluation of care pathways and the impact of the movement toward value-based care.

The National Comprehensive Cancer Network (NCCN) Thursday released its first set of clinical practice guidelines for pediatric cancer, saying the new acute lymphoblastic leukemia (ALL) guidelines are the first of several planned to address various pediatric cancers.

Updates on reporting otucomes and pathway design from Patient-Centered Oncology Care®.

The authors, led by Kashyap Patel, MD, offer the first in a series of articles on how Carolina Blood and Cancer Care Associates leveraged the strength of its team to take part in the Oncology Care Model.

Molly MacDonald, the founder and CEO of The Pink Fund, writes about how patients with breast cancer can approach decisions about choosing among disparate treatment protocols.

A recent study of abemaciclib, a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer, found that it helped all women with hormone receptor–positive, human epidermal growth factor receptor 2–negative disease, and that it was particularly beneficial in women with a worse prognosis.

During the San Antonio Breast Cancer Symposium held in San Antonio, Texas from December 4-8, 2018, Biotheranostics presented new data evaluating the impact of the Breast Cancer Index (BCI) in patients with early stage hormone receptor positive (HR+) breast cancer who are classified as an immediate risk for distant recurrence by previous genomic testing.

Competing breast cancer tests vie for attention from clinicians and payers at the San Antonio Breast Cancer Symposium.

BioNTech AG, a drug developer that specializes in cancer immunotherapies, announced last month new results from a clinical performance evaluation study of a molecular in vitro diagnostic test for quantitative detection of mRNA expression of certain genes.

In a multicenter study, only 1 in 5 women at increased risk of breast cancer reported a strong need for tamoxifen preventive therapy, according to a report published Monday.

In a study presented at the annual meeting of the Radiological Society of North America (RSNA), researchers found that starting mammography screening at age 30 may benefit women with at least 1 of 3 risk factors: dense breasts, a personal history of breast cancer, or a family history of breast cancer.

Fibroblasts play a role in the spread of cancer, and a recent study showed that breast tumors can boost their growth by recruiting bone marrow–derived mesenchymal stromal cells to primary breast tumors

The Abramson Cancer Center of the University of Pennsylvania will become the 28th member institution to join the National Comprehensive Cancer Network (NCCN), it was announced Tuesday.

A recent review looked at the role lipocalin 2 (LCN2), a secreted glycoprotein that transports small lipophilic ligands, might play in metastatic triple-negative breast cancer (TNBC) and the possibility of potential LCN2-targeting agents.

A recent study sought to learn more about how estrogen receptor signaling occurs in vivo in normal and cancerous tissue.